

The Chemours Company

First Quarter 2020 Earnings Presentation

May 6, 2020



Safe Harbor Statement and Other Matters

This presentation contains forward-looking statements, within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words "believe," "expect," "will," "anticipate," "plan," "estimate," "target," "project" and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date such statements were made. These forward-looking statements may address, among other things, the outcome or resolution of any pending or future environmental liabilities, the commencement, outcome or resolution of any regulatory inquiry, investigation or proceeding, the initiation, outcome or settlement of any litigation, changes in environmental regulations in the U.S. or other jurisdictions that affect demand for or adoption of our products, anticipated future operating and financial performance, business plans, prospects, targets, goals and commitments, capital investments and projects, plans for dividends or share repurchases, sufficiency or longevity of intellectual property protection, cost reductions or savings targets, plans to increase profitability and growth, our ability to make acquisitions, integrate acquired businesses or assets into our operations, and achieve anticipated synergies or cost savings, all of which are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized. These statements are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties that are beyond Chemours' control. In addition, the current COVID-19 pandemic has significantly impacted the national and global economy and commodity and financial markets. The full extent and impact of the pandemic is unknown and to date has included extreme volatility in financial and commodity markets, a significant slowdown in economic activity, and increased predictions of a global recession. The public and private sector response has led to significant restrictions on travel, temporary business closures, quarantines, stock market volatility, and a general reduction in consumer and commercial activity globally. Matters outside our control have affected our business and operations and may or may continue to limit travel of employees to our business units domestically and internationally, adversely affect the health and welfare of our personnel, significantly reduce the demand for our products, hinder our ability to provide goods and services to customers, cause disruptions in our supply chains, adversely affect our business partners or cause other unpredictable events. Additionally, there may be other risks and uncertainties that Chemours is unable to identify at this time or that Chemours does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include the risks, uncertainties and other factors discussed in our filings with the U.S. Securities and Exchange Commission, including in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 and in our Annual Report on Form 10-K for the year ended December 31, 2019. Chemours assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.

We prepare our financial statements in accordance with Generally Accepted Accounting Principles ("GAAP"). Within this presentation we may make reference to Adjusted Net Income, Adjusted EPS, Adjusted EBITDA, Adjusted EBITDA Margin, Free Cash Flow, Adjusted Effective Tax Rate, Return on Invested Capital (ROIC) and Net Leverage Ratio which are non-GAAP financial measures. The company includes these non-GAAP financial measures because management believes they are useful to investors in that they provide for greater transparency with respect to supplemental information used by management in its financial and operational decision making. Further information with respect to and reconciliations of such measures to the nearest GAAP measure can be found in the appendix hereto.

Management uses Adjusted Net Income, Adjusted EPS, Adjusted EBITDA, Adjusted EBITDA Margin, Free Cash Flow, Adjusted Effective Tax Rate, ROIC and Net Leverage Ratio to evaluate the company's performance excluding the impact of certain noncash charges and other special items which we expect to be infrequent in occurrence in order to have comparable financial results to analyze changes in our underlying business from quarter to quarter.

Additional information for investors is available on the company's website at investors.chemours.com.

First Quarter 2020 Highlights

Protecting the safety of our Employees while supporting our Customers

Delivered a solid Q1 2020 following a strong Q4 2019

Navigating uncertain market conditions with strong value proposition

Preserving strong balance sheet and liquidity

Taking bold actions to reduce spending and conserve cash



Chemours COVID-19 Response – Actions to reduce spending and conserve cash

Protecting the safety of our Employees while supporting our Customers

Cost Deferrals / Reductions ~\$160M

- Reducing discretionary spend
- Implementing hiring freeze for non-critical employees
- Delaying external spending
- Optimizing plant fixed costs
- Taking temporary CEO & leadership compensation actions

CAPEX Reductions ~\$125M

- Targeting reduction of \$125M
 - Reductions primarily focused on growth projects

First Quarter 2020 Financial Summary

(\$ in millions unless otherwise noted)

	1Q20	1Q19	Δ Yr/Yr
Net Sales	\$1,305	\$1,376	\$(71)
Net Income ¹	100	94	6
Adj. Net Income	118	109	9
EPS ²	\$0.61	\$0.55	\$0.06
Adj. EPS ²	\$0.71	\$0.63	\$0.08
Adj. EBITDA	257	262	(5)
Adj. EBITDA Margin (%) ³	20	19	1
Free Cash Flow ⁴	(62)	(177)	115
Pre-Tax ROIC (%) ⁵	17	32	(15)

Year-Over-Year

- Sales down 5 percent from 1Q19
- Adjusted EBITDA decline primarily driven by lower volumes and prices in Fluoroproducts
- GAAP EPS of \$0.61 and Adjusted EPS of \$0.71 up 11% and 13% respectively
- Free Cash Flow of \$(62) million includes \$106 million capital expenditures in the quarter, and reflects benefit from the amended and restated AR securitization facility
- On April 28th, the company's board of directors approved a Q2 dividend of \$0.25 per share, consistent with the prior quarter

¹ Net Income attributable to The Chemours Company

² Calculation based on diluted share count

³ Defined as Adjusted EBITDA divided by Net Sales

⁴ Defined as cash from operations minus cash used for PP&E purchases


⁵ Defined as Adjusted EBITDA less depreciation & amortization on a trailing twelve-month basis divided by average invested capital over the last five quarters

See reconciliation of Non-GAAP measures in the Appendix

Adjusted EBITDA Bridge: 1Q20 versus 1Q19

(\$ in millions unless otherwise noted)


- Positive Impact
- Negative Impact



Liquidity Position

(\$ in millions unless otherwise noted)

- Negative Impact
- Positive Impact



- March 31, 2020 ending cash balance of \$714M, reflecting normal seasonal Net Working Capital use of cash
- 1Q20 capital expenditures of \$106M
- 1Q20 dividends of \$41M
- Total Liquidity of ~\$1.4B including revolver availability of \$699M¹ as of March 31, 2020
 - *Drew \$300M from revolving credit facility on April 8, 2020 as a precautionary measure*
- Gross debt of \$4.1B, net debt of \$3.4B; net leverage ratio² of ~3.3x times on a trailing twelve-month Adjusted EBITDA basis

¹ Net of \$101M in letters of credit outstanding as of March 31, 2020.

² Senior Secured Net Debt/EBITDA is ~0.7x based on Credit Agreement definition as of March 31, 2020

³ Other reflects \$110M of debt reduction in connection with the amended and restated AR Securitization facility; related benefit reflected in Operating Cash Flow

Balance Sheet Strength and Flexibility

Significant Liquidity


- Total Liquidity of \$1.4B as of March 31, 2020
 - Global cash \$714M
 - Revolver availability, net of letters of credit: \$699M
- Balanced global cash distribution with \$386M US cash position
- Subsequent to the end of Q1, drew \$300M from the revolving credit facility as a precautionary measure

Ample Covenant Headroom in Q1

- Maintenance Covenant: Senior Secured Net Leverage Ratio less than 2.0x
 - Current Ratio = ~0.7x
- Gross Senior Secured Debt: \$1.3B
 - Less Cash: \$714M (\$750M maximum offset)

No Near Term Maturities

Current Maturity Profile



¹ USD Notes (NC3) & \$800M ABL Revolver.

² USD Notes (NC5), USD Term Loan B, Euro Term Loan B. In 2023, Revolver and Term Loans are subject to a springing maturity if 2023 notes are not redeemed or refinanced 91 days prior to maturity date

³ Euro Notes (NC3)

⁴ USD Notes (NCL)



Fluoroproducts Business Summary

First Quarter


- Experienced lower demand primarily driven by lower volume in Asia Pacific, auto OEM shutdowns, and lower volumes in several other industrial end markets globally
- Achieved steady year-over-year volume growth of Opteon™ blends, while quota sales still impacted by HFC illegal imports into the EU
- Delivered strong sequential margin improvement driven by increased cost benefits from the Corpus Christi Opteon™ facility ramp up, better operational execution and productivity across the business

2020 Outlook

- Actively adjusting supply chain to account for uncertain demand environment
- Focusing on factors within our control to manage production, inventories and cost reductions / deferrals
- Driving regulatory initiatives and making investments to control illegal imports of HFC refrigerants into the EU

First Quarter 2020 Financial Summary (\$ in millions)


Quarterly Net Sales



Quarterly Sales Drivers

	Yr/Yr % Δ
Price	(4)
Volume	(8)
Currency	(1)

Quarterly Adjusted EBITDA



Chemical Solutions Business Summary

First Quarter


- Experienced lower revenue/volume driven by MAP business divestiture and lower cost pass-throughs
- Delivered flat year-over-year earnings, reflecting lower demand in some products offset by lower operating cost
- Achieved 500bps of margin improvement year-over-year

2020 Outlook

- Continued focus on productivity, inventory management and cash generation
- Expect demand to normalize once customer mines return to full operation

First Quarter 2020 Financial Summary (\$ in millions)


Quarterly Net Sales



Quarterly Sales Drivers

	Yr/Yr % Δ
Price	(4)
Volume	(7)
Currency	(0)
Other / Portfolio ¹	(20)

Quarterly Adjusted EBITDA



Titanium Technologies Business Summary

First Quarter


- Achieved volume increases across all regions and most end markets on both a year-over-year and sequential basis as a result of share regain
- Delivered 400bps of sequential margin expansion primarily driven by volume strength and operations performance partially offset by impacts of price mix
- Saw continued progress in TVS channel adoption with expanded AVA agreements and increased sales through Flex portal

2020 Outlook

- Monitoring the impact of COVID-19 and maintaining close engagement with customers to respond to their changing needs during this dynamic time
- AVA: Demonstrating our TVS value proposition through contracted supply assurance, consumption-based volume agreements and predictable pricing
- Flex Portal: Serving customers through our online portal with ability to lock in supply and pricing up to 6 months in advance
- Our Distributor Partners: Extending Ti-Pure™ reach to serve a broader customer base

First Quarter 2020 Financial Summary (\$ in millions)


Quarterly Net Sales



Quarterly Sales Drivers

	Yr/Yr % Δ
Price	(8)
Volume	19
Currency	(1)

Quarterly Adjusted EBITDA



Chemours is taking action in response to COVID-19

Putting Employees and Customers First

- Strong, proactive health and safety measures across our sites
- Limited number of COVID-19 cases worldwide
- As of today, all sites operational, Chemours open for business

Maintaining a Strong Balance Sheet and Liquidity Position

- \$1.4 billion of total liquidity
- \$1.0 billion of cash (including \$300M revolving credit facility draw)
- No near term senior debt maturities, with well spaced and balanced maturity profile

Acting to Create Additional Financial Flexibility in 2020

- \$125 million CAPEX reduction
- \$160 million FY2020 cost reduction program



The Chemours Company

Appendix



Segment Net Sales and Adjusted EBITDA (Unaudited)

(\$ in millions)

	Three Months Ended		Three Months Ended
	March 31,		December 31,
	2020	2019	2019
SEGMENT NET SALES			
Fluoroproducts	\$ 600	\$ 687	\$ 614
Chemical Solutions	92	134	129
Titanium Technologies	613	555	610
Total Company	<u>\$ 1,305</u>	<u>\$ 1,376</u>	<u>\$ 1,353</u>
SEGMENT ADJUSTED EBITDA			
Fluoroproducts	\$ 140	\$ 159	\$ 117
Chemical Solutions	15	15	25
Titanium Technologies	138	126	115
Corporate and Other	(36)	(38)	(30)
Total Company	<u>\$ 257</u>	<u>\$ 262</u>	<u>\$ 227</u>
SEGMENT ADJUSTED EBITDA MARGIN			
Fluoroproducts	23%	23%	19%
Chemical Solutions	16%	11%	19%
Titanium Technologies	23%	23%	19%
Corporate and Other	—	—	—
Total Company	<u>20%</u>	<u>19%</u>	<u>17%</u>

GAAP Net Income Attributable to Chemours to Adjusted Net Income, Adjusted EBITDA, and Adjusted EPS Reconciliations (Unaudited)

(\$ in millions except per share amounts)

	Three Months Ended				Three Months Ended	
	March 31,				December 31,	
	2020		2019		2019	
	\$ amounts	\$ per share*	\$ amounts	\$ per share*	\$ amounts	\$ per share*
Net income (loss) attributable to Chemours (1)	\$ 100	\$ 0.61	\$ 94	\$ 0.55	\$ (317)	\$ (1.94)
Non-operating pension and other post-retirement employee benefit (income) cost	-	-	(3)	(0.02)	373	2.26
Exchange losses (gains), net	24	0.15	(6)	(0.03)	4	0.02
Restructuring, asset-related, and other charges	11	0.07	8	0.05	38	0.23
Loss on sales of assets and businesses	-	-	-	-	1	0.01
Transaction costs	2	0.01	-	-	2	0.01
Legal and environmental charges	10	0.06	29	0.17	132	0.80
Adjustments made to income taxes	(19)	(0.11)	(5)	(0.03)	(5)	(0.03)
Benefit from income taxes relating to reconciling items	(10)	(0.06)	(8)	(0.05)	(136)	(0.82)
Adjusted Net Income (1)	\$ 118	\$ 0.71	\$ 109	\$ 0.63	\$ 92	\$ 0.56
Interest expense, net	54		51		52	
Depreciation and amortization	79		76		79	
All remaining provision for income taxes	6		26		4	
Adjusted EBITDA	\$ 257		\$ 262		\$ 227	
Weighted-average number of common shares outstanding - basic	164,247,449		167,866,468		163,519,362	
Weighted-average number of common shares outstanding - diluted (1)	165,257,991		172,060,900		164,889,475	
Basic earnings (loss) per share of common stock	\$ 0.61		\$ 0.56		\$ (1.94)	
Diluted earnings (loss) per share of common stock (1)	0.61		0.55		(1.94)	
Adjusted basic earnings per share of common stock	0.72		0.65		0.56	
Adjusted diluted earnings per share of common stock (1)	0.71		0.63		0.56	

(1) In periods where the Company incurs a net loss, the impact of potentially dilutive securities is excluded from the calculation of EPS under U.S. GAAP, as their inclusion would have an anti-dilutive effect. As such, with respect to the U.S. GAAP measure of diluted EPS, the impact of potentially dilutive securities is excluded from our calculation for the three months ended December 31, 2019. With respect to the non-GAAP measure of adjusted diluted EPS, the impact of potentially dilutive securities is included in our calculation for the three months ended December 31, 2019, as Adjusted Net Income was in a net income position.

* Note: \$ per share columns may not sum due to rounding.



Return on Invested Capital (ROIC) (Unaudited)

(\$ in millions)

Adjusted EBITDA (1)
 Less: Depreciation and amortization (1)
Adjusted EBIT

	Twelve Months Ended March 31,	
	2020	2019
\$	1,015	\$ 1,535
	(313)	(289)
\$	702	\$ 1,246

(\$ in millions)

Total debt
 Total equity
 Less: Cash and cash equivalents
Invested capital, net
 Average invested capital (2)

	As of March 31,	
	2020	2019
\$	4,034	\$ 3,978
	661	816
	(714)	(697)
\$	3,981	\$ 4,097
\$	4,140	\$ 3,853

Return on Invested Capital

17% 32%

(1) See the reconciliation of Adjusted EBITDA to net income (loss) attributable to Chemours on the previous slide.

(2) Average invested capital is based on a five-quarter trailing average of invested capital, net.



Free Cash Flows Reconciliations (Unaudited)

(\$ in millions)

	Three Months Ended		
	March 31,		December 31,
	2020	2019	2019
Cash flows provided by (used for) operating activities	\$ 44	\$ (44)	\$ 400
Less: Purchases of property, plant, and equipment	(106)	(133)	(96)
Free Cash Flows	\$ (62)	\$ (177)	\$ 304



The Chemours Company

